There’s no ASCO meeting without the Bean

There’s always a parable or two to be had at ASCO and this year was no different, especially in the breast cancer space where there were plenty of phase 2 and 3 trials to discuss as well as offer commentary on the various findings.

Not all of the results were standouts though, with some creating controversy in the process.

Here, we take a look at some examples and put them in context…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

 

 

Posted by